Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Resources › Webinars › The Case for a Universal FLT3 Assay
July 25, 2019

The Case for a Universal FLT3 Assay

Partner Webinar

Join or Log in for Access

This content is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

This on-demand webinar from Invivoscribe describes the advantages of using a highly validated and precise companion diagnostic in the assessment of FLT3 mutations in AML patients.

Sep
24
Featured Webinar

New Insights Underscore the Need to Identify NTRK Fusions in Childhood Tumors

NTRK fusions are oncogenic drivers in a variety of tumors.

Oct
08
Featured Webinar

Novel Applications of RNA-based Precision Oncology: From Drug Tolerability to Immunogenomics

Sponsored by
Genecentric

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

Oct
14
Featured Webinar

Application of ctDNA Analysis to Detect MRD and Predict Recurrence in Colorectal Cancer

Sponsored by
Inivata

Circulating tumor DNA (ctDNA) can allow clinicians and researchers to better understand which patients are at high risk of recurrence and should be offered intensified chemotherapy or selected for clinical trials.

Oct
15
Featured Webinar

A Comparison of cfDNA Approaches to Guide Targeted Therapy in NSCLC

In non-small cell lung cancer (NSCLC), early detection of emerging resistance mutations such as EGFR T790M is important in order to determine the appropriate targeted therapeutic strategy.

What's Popular?

In Cancer

  1. Startup Stitch Bio Bets on CRISPR Tech to Render Cancer Cells With Gene Fusions Druggable

    Premium

  2. Pfizer Pursuing Multiple Biomarker-Defined Cancer Indications in Coming Years

    Premium

  3. Foundation Medicine, Takeda Collaborate to Develop CDx for NSCLC Therapies

  4. BMS' Opdivo Garners Positive Draft Recommendation From UK's NICE in Second-Line NSCLC

  5. Yufan Biotech, Abound Bio Partner on HPK1-Inhibiting CAR T-Cell Therapies

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.